Miltenyi Biomedicine GmbH
- Country
- 🇧🇪Belgium
- Ownership
- Private
- Established
- 2019-01-01
- Employees
- 51
- Market Cap
- -
US Zamto-cel Autoimmune Diseases
- Conditions
- Interventions
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT06708845
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 40
- Registration Number
- NCT06508775
- Locations
- 🇩🇪
Universitätsklinikum Köln, Cologne, Germany
🇩🇪Universitätsmedizin Göttingen, Göttingen, Germany
🇩🇪Universitätsklinikum Münster, Münster, Germany
Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With Relapsed or Refractory B-Cell Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 31
- Registration Number
- NCT06508931
MB-dNPM1-TCR.1 in Relapsed/refractory AML
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 29
- Registration Number
- NCT06424340
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
M-2018-334 in Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 18
- Registration Number
- NCT06225050
MB-CART19.1 in Refractory SLE
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 29
- Registration Number
- NCT06189157
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Medizinische Klinik 3, Erlangen, Germany
🇩🇪Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany
🇩🇪Universitatsklinikum Tubingen - Medizinische Universitätsklinik Abt. II, Tübingen, Germany
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 150
- Registration Number
- NCT06116110
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 168
- Registration Number
- NCT04844866
- Locations
- 🇪🇸
Hospital Clinic de Barcelona (Hospital Clinic i Provincial), Barcelona, Spain
🇦🇹Medizinische Universitaetsklinik Graz, Graz, Austria
🇦🇹Universitatsklinikum Innsbruck Universitatsklinik fur Innere Medizin V, Innsbruck, Austria
DALY II USA/ MB-CART2019.1 for DLBCL
- Conditions
- Interventions
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 110
- Registration Number
- NCT04792489
- Locations
- 🇺🇸
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Duke University Medical Center - Division of Hematologic Malignancies, Durham, North Carolina, United States
🇺🇸Stanford University, Stanford, California, United States
A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 417
- Registration Number
- NCT04405466
- Locations
- 🇩🇪
Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, NRW, Germany